Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations

Detalhes bibliográficos
Autor(a) principal: Pérez,O.
Data de Publicação: 2012
Outros Autores: Batista-Duharte,A., González,E., Zayas,C., Balboa,J., Cuello,M., Cabrera,O., Lastre,M., Schijns,V.E.J.C.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Medical and Biological Research
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000800001
Resumo: Adjuvants have been considered for a long time to be an accessory and empirical component of vaccine formulations. However, accumulating evidence of their crucial role in initiating and directing the immune response has increased our awareness of the importance of adjuvant research in the past decade. Nevertheless, the importance of adjuvants still is not fully realized by many researchers working in the vaccine field, who are involved mostly in the search for better target antigens. The choice of a proper adjuvant can be determinant for obtaining the best results for a given vaccine candidate, but it is restricted due to intellectual property and know-how issues. Consequently, in most cases the selected adjuvant continues to be the aluminum salt, which has a record of safety, but predominantly constitutes a delivery system (DS). Ideally, new strategies should combine immune potentiators (IP) and DS by mixing both compounds or by obtaining structures that contain both IP and DS. In addition, the term immune polarizer has been introduced as an essential concept in the vaccine design strategies. Here, we review the theme, with emphasis on the discussion of the few licensed new adjuvants, the need for safe mucosal adjuvants and the adjuvant/immunopotentiating activity of conjugation. A summary of toxicology and regulatory issues will also be discussed, and the Finlay Adjuvant Platform is briefly summarized.
id ABDC-1_ccaa0233a89c1ad647458b0a1412b509
oai_identifier_str oai:scielo:S0100-879X2012000800001
network_acronym_str ABDC-1
network_name_str Brazilian Journal of Medical and Biological Research
repository_id_str
spelling Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulationsHuman vaccinesAdjuvantsFinlay adjuvantsAFPL1AFCo1Adjuvants have been considered for a long time to be an accessory and empirical component of vaccine formulations. However, accumulating evidence of their crucial role in initiating and directing the immune response has increased our awareness of the importance of adjuvant research in the past decade. Nevertheless, the importance of adjuvants still is not fully realized by many researchers working in the vaccine field, who are involved mostly in the search for better target antigens. The choice of a proper adjuvant can be determinant for obtaining the best results for a given vaccine candidate, but it is restricted due to intellectual property and know-how issues. Consequently, in most cases the selected adjuvant continues to be the aluminum salt, which has a record of safety, but predominantly constitutes a delivery system (DS). Ideally, new strategies should combine immune potentiators (IP) and DS by mixing both compounds or by obtaining structures that contain both IP and DS. In addition, the term immune polarizer has been introduced as an essential concept in the vaccine design strategies. Here, we review the theme, with emphasis on the discussion of the few licensed new adjuvants, the need for safe mucosal adjuvants and the adjuvant/immunopotentiating activity of conjugation. A summary of toxicology and regulatory issues will also be discussed, and the Finlay Adjuvant Platform is briefly summarized.Associação Brasileira de Divulgação Científica2012-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000800001Brazilian Journal of Medical and Biological Research v.45 n.8 2012reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X2012007500067info:eu-repo/semantics/openAccessPérez,O.Batista-Duharte,A.González,E.Zayas,C.Balboa,J.Cuello,M.Cabrera,O.Lastre,M.Schijns,V.E.J.C.eng2012-07-31T00:00:00Zoai:scielo:S0100-879X2012000800001Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2012-07-31T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false
dc.title.none.fl_str_mv Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
title Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
spellingShingle Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
Pérez,O.
Human vaccines
Adjuvants
Finlay adjuvants
AFPL1
AFCo1
title_short Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
title_full Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
title_fullStr Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
title_full_unstemmed Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
title_sort Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations
author Pérez,O.
author_facet Pérez,O.
Batista-Duharte,A.
González,E.
Zayas,C.
Balboa,J.
Cuello,M.
Cabrera,O.
Lastre,M.
Schijns,V.E.J.C.
author_role author
author2 Batista-Duharte,A.
González,E.
Zayas,C.
Balboa,J.
Cuello,M.
Cabrera,O.
Lastre,M.
Schijns,V.E.J.C.
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pérez,O.
Batista-Duharte,A.
González,E.
Zayas,C.
Balboa,J.
Cuello,M.
Cabrera,O.
Lastre,M.
Schijns,V.E.J.C.
dc.subject.por.fl_str_mv Human vaccines
Adjuvants
Finlay adjuvants
AFPL1
AFCo1
topic Human vaccines
Adjuvants
Finlay adjuvants
AFPL1
AFCo1
description Adjuvants have been considered for a long time to be an accessory and empirical component of vaccine formulations. However, accumulating evidence of their crucial role in initiating and directing the immune response has increased our awareness of the importance of adjuvant research in the past decade. Nevertheless, the importance of adjuvants still is not fully realized by many researchers working in the vaccine field, who are involved mostly in the search for better target antigens. The choice of a proper adjuvant can be determinant for obtaining the best results for a given vaccine candidate, but it is restricted due to intellectual property and know-how issues. Consequently, in most cases the selected adjuvant continues to be the aluminum salt, which has a record of safety, but predominantly constitutes a delivery system (DS). Ideally, new strategies should combine immune potentiators (IP) and DS by mixing both compounds or by obtaining structures that contain both IP and DS. In addition, the term immune polarizer has been introduced as an essential concept in the vaccine design strategies. Here, we review the theme, with emphasis on the discussion of the few licensed new adjuvants, the need for safe mucosal adjuvants and the adjuvant/immunopotentiating activity of conjugation. A summary of toxicology and regulatory issues will also be discussed, and the Finlay Adjuvant Platform is briefly summarized.
publishDate 2012
dc.date.none.fl_str_mv 2012-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000800001
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000800001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0100-879X2012007500067
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
dc.source.none.fl_str_mv Brazilian Journal of Medical and Biological Research v.45 n.8 2012
reponame:Brazilian Journal of Medical and Biological Research
instname:Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
instname_str Associação Brasileira de Divulgação Científica (ABDC)
instacron_str ABDC
institution ABDC
reponame_str Brazilian Journal of Medical and Biological Research
collection Brazilian Journal of Medical and Biological Research
repository.name.fl_str_mv Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)
repository.mail.fl_str_mv bjournal@terra.com.br||bjournal@terra.com.br
_version_ 1754302941534093312